What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share gains.
Overview
On June 22, 2026, David Lowrance, the Chief Financial Officer of Savara (NASDAQ:SVRA), executed the exercise of 580,187 options on Common Stock followed by the sale of 394,528 shares in the open market, as reported in this SEC Form 4 filing.
Transaction and post-transaction values based on SEC Form 4 weighted average purchase price of $5.68 on June 22, 2026.
Details
* 1-year performance calculated using June 22, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.